PT-141 (also known as Bremelanotide) is a synthetic peptide that activates melanocortin receptors in the brain, working through the central nervous system to influence sexual desire and arousal. This is fundamentally different from medications like sildenafil (Viagra) or tadalafil (Cialis), which work peripherally by improving blood flow to address erectile function but do not directly affect desire.

PT-141 is the active ingredient in Vyleesi, an FDA-approved medication for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD) — making it one of the few peptides in this category with genuine regulatory approval for a specific medical indication.

PT-141 binds to melanocortin receptors (primarily MC4R) concentrated in the brain's central nervous system, activating neural pathways involved in sexual arousal and motivation. This central mechanism is why it can address low desire even in cases where the cause isn't primarily related to blood flow — for instance, up to 50% of men with diabetes and erectile dysfunction don't respond adequately to PDE5 inhibitors, highlighting the need for therapies that work through different pathways.

FDA-approved use (as Vyleesi): treatment of acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women.

Off-label/wellness use: some clinics use PT-141 for men experiencing low libido or erectile dysfunction not adequately addressed by standard treatments, though this use is supported by a smaller body of clinical evidence compared to the approved female indication. Medilife's medical team will discuss the appropriate evidence base for your specific situation during consultation, being transparent about what is established versus emerging use.

PT-141 is typically administered via subcutaneous injection, with standard protocols suggesting 1.75–2mg administered 45–60 minutes before anticipated activity. It begins working within about an hour as it acts through the central nervous system rather than requiring time for vascular changes. Some compounded formulations are also available as a nasal spray, though this route has less robust clinical trial data behind it compared to the approved injection.

The most commonly reported side effects, based on clinical trial data for the approved formulation, include:

• Nausea (reported in a significant proportion of users, particularly with higher doses)
• Flushing, especially in the first hour after dosing
• Headache
• Injection-site reactions (redness, soreness)
• Transient increases in blood pressure

Some users may also notice mild skin pigmentation changes or darkening of existing moles, as PT-141 is derived from a tanning-related compound (Melanotan II), though this effect is less pronounced than with its parent compound. PT-141 is contraindicated in uncontrolled hypertension and cardiovascular disease — disclosing your full medical history during consultation is essential.

Frequent use — more than once a week — tends to lead to diminished effects over time for many users. Most clinical and user-reported guidance recommends spacing doses at least 7 to 14 days apart for the treatment to remain effective. Your Medilife physician will determine the most appropriate frequency for your specific situation based on the approved label guidance and your response to initial doses.

Some research suggests combining PT-141 with a PDE5 inhibitor may produce enhanced effects, since the two work through different mechanisms — PT-141 centrally on desire, PDE5 inhibitors peripherally on blood flow. There is no direct pharmacological contraindication between the two, though cardiovascular caution still applies to both. This combination should only be considered under direct medical guidance, as your Medilife physician will assess whether this is appropriate based on your cardiovascular health and current medications.

PT-141 is not suitable for everyone. It is specifically contraindicated for individuals with uncontrolled hypertension or known cardiovascular disease, due to its effect on transiently raising blood pressure. It is also not appropriate during pregnancy. A thorough medical assessment, including discussion of your cardiovascular health and current medications, is required before Medilife will administer PT-141.

Yes. As a peptide with an approved pharmaceutical indication, PT-141 should only be obtained and administered through a licensed medical provider following a proper consultation and prescription. Medilife requires a full medical assessment before administering PT-141, ensuring it is genuinely appropriate for your health profile rather than self-directed or sourced from unregulated channels, which carry significant safety risks due to unknown purity and dosing.

Yes, following an initial medical consultation to confirm suitability and establish the correct dosing protocol, Medilife's qualified clinical team can administer PT-141 at your home with complete privacy and discretion. This consultation-first approach ensures your safety while offering the convenience and confidentiality many clients value for sexual health treatments.